# Chione

> Chione is a VC fund in Berlin backing Health Care, Biotechnology and Sensor. See 7 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: Berlin, Germany
- Total investments: 7
- Last investment: Oct 2025
- Lead investor: 29%
- Last updated: Aug 2026

Chione is an investment company that aims to finance companies in the biomedical sector.

## Round sizes

| Stage | Round size |
| --- | --- |
| Series B | $5M–$100M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 2 | 29% |
| Biotechnology | 2 | 29% |
| Sensor | 1 | 14% |
| Medical | 1 | 14% |
| Hospital | 1 | 14% |

19 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 2 | 29% |
| Series A | 1 | 14% |
| Series C | 1 | 14% |
| Series D | 1 | 14% |
| Funding Round | 1 | 14% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 2 | 29% |
| Israel | 1 | 14% |
| Finland | 1 | 14% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Prisma Photonics | Prisma photonics helps to keep the most critical large-scale infrastructure running. Introducing the next generation of utility monitoring paving the way to smarter, safe, and efficient operations. We empower our customers and provide them with the best actionable insights on their assets, enabling them to move to a new era of digitalization.Prisma Photonics was founded in 2017 by a strong team of entrepreneurs, highly experienced in lasers, optical fiber, algorithms, and machine learning. Combining talent from the physics and laser world with algorithmic and machine learning expertise. The company is now in commercial deployment stage. | $30M |  | Oct 15, 2025 |  |
| Prisma Photonics | Prisma photonics helps to keep the most critical large-scale infrastructure running. Introducing the next generation of utility monitoring paving the way to smarter, safe, and efficient operations. We empower our customers and provide them with the best actionable insights on their assets, enabling them to move to a new era of digitalization.Prisma Photonics was founded in 2017 by a strong team of entrepreneurs, highly experienced in lasers, optical fiber, algorithms, and machine learning. Combining talent from the physics and laser world with algorithmic and machine learning expertise. The company is now in commercial deployment stage. | $20M | Series C | Sep 12, 2023 |  |
| ICEYE | ICEYE is a space technology company that develops and operates a constellation of synthetic aperture radar (SAR) satellites used for Earth observation and persistent monitoring. The company provides satellite imagery and data that enable governments, defense organizations, insurers, financial institutions, and other commercial users to monitoractivities and environmental conditions across the globe. Its SAR technology captures imagery regardless of cloud cover, weather conditions, or time of day, supporting applications such as disaster response, infrastructure monitoring, maritime awareness, environmental monitoring, and security operations. ICEYE also delivers satellite-based intelligence systems and analytical solutions that help organizations assess events, track changes, and make operational decisions using near real-time information. Through its satellite network and data services, the company supports monitoring and situational awareness across a range of public and commercial sectors. | $136M | Series D | Feb 03, 2022 |  |
| Acrivon Therapeutics | Acrivon Therapeutics is a precision oncology therapeutics company specializing in drug development through early clinical treatment success. They specifically apply its approach to challenging oncology drug targets causally implicated in the vast majority of cancers, particularly those without simple single-gene driver mutations or synthetic lethalcontexts. The company aims to rapidly progress in-licensed clinical-stage assets and a pipeline of internally developed programs through accelerated registration trials. | $100M | Series B | Nov 11, 2021 |  |
| Prisma Photonics | Prisma photonics helps to keep the most critical large-scale infrastructure running. Introducing the next generation of utility monitoring paving the way to smarter, safe, and efficient operations. We empower our customers and provide them with the best actionable insights on their assets, enabling them to move to a new era of digitalization.Prisma Photonics was founded in 2017 by a strong team of entrepreneurs, highly experienced in lasers, optical fiber, algorithms, and machine learning. Combining talent from the physics and laser world with algorithmic and machine learning expertise. The company is now in commercial deployment stage. | $10M | Series A | Jan 01, 2020 |  |
| Sera Prognostics | Sera is a women’s health diagnostics company dedicated to improving the lives of women and babies through precision pregnancy care. Sera provides pivotal information during pregnancy to physicians, designed to help improve the health of their patients, and to reduce the costs of healthcare delivery. Sera has a robust pipeline of innovativediagnostic tests focused on the prediction of preterm birth risk and other complications of pregnancy. Sera’s PreTRM® Test reports to a physician the individualized risk of spontaneous premature delivery in a pregnancy, enabling earlier proactive interventions in women with higher risk. | $20M | Series B | Jan 07, 2015 |  |
| Sera Prognostics | Sera is a women’s health diagnostics company dedicated to improving the lives of women and babies through precision pregnancy care. Sera provides pivotal information during pregnancy to physicians, designed to help improve the health of their patients, and to reduce the costs of healthcare delivery. Sera has a robust pipeline of innovativediagnostic tests focused on the prediction of preterm birth risk and other complications of pregnancy. Sera’s PreTRM® Test reports to a physician the individualized risk of spontaneous premature delivery in a pregnancy, enabling earlier proactive interventions in women with higher risk. | $5M | Series B | Nov 18, 2014 |  |

7 of 7 investments shown.

## Co-investors
- [Catalyst Health Ventures](https://shizune.co/investors/profile/catalyst-health-technology-partners) — VC Fund, 2 deals together
- [Catalyst Health Ventures](https://shizune.co/investors/profile/catalyst-health-ventures) — VC Fund, 2 deals together
- [Domain Associates](https://shizune.co/investors/profile/domain-associates) — VC Fund, 2 deals together
- [Insight Partners](https://shizune.co/investors/profile/insight-partners) — VC Fund, 2 deals together
- [SE Ventures](https://shizune.co/investors/profile/schneider-electric-ventures) — VC Fund, 2 deals together
- [Seraphim Space](https://shizune.co/investors/profile/seraphim-capital) — VC Fund, 2 deals together

## Similar investors

### Similar industry
- [Chevron Technology Ventures](https://shizune.co/investors/profile/chevron-technology-ventures) — VC Fund
- [Evok Innovations](https://shizune.co/investors/profile/evok-innovations) — VC Fund
- [Scottish Enterprise](https://shizune.co/investors/profile/scottish-enterprise) — VC Fund

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

### Similar country
- [OurCrowd](https://shizune.co/investors/profile/ourcrowd) — VC Fund
- [Entrée Capital](https://shizune.co/investors/profile/entree-capital) — VC Fund
- [Pitango VC](https://shizune.co/investors/profile/pitango-venture-capital) — VC Fund

## Featured in investor lists
- [Oil and Gas Investors in Israel](https://shizune.co/investors/oil-and-gas-investors-israel)
- [Oil and Gas VC Funds in Israel](https://shizune.co/investors/oil-and-gas-vc-funds-israel)
- [Sustainability VC Funds in Israel](https://shizune.co/investors/sustainability-vc-funds-israel)
- [Impact VC Funds in Israel](https://shizune.co/investors/impact-vc-funds-israel)
- [Infrastructure VC Funds in Middle East](https://shizune.co/investors/infrastructure-vc-funds-middle-east)
- [Infrastructure Investors in Israel](https://shizune.co/investors/infrastructure-investors-israel)

## FAQ

### What does Chione invest in?

Chione invests primarily in Health Care, Biotechnology and Sensor startups, most often at Series B and Series A stage. Most of the 7 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Chione's check size?

Chione typically joins rounds of $5M–$100M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Chione participates in.

### When did Chione last invest?

The most recent investment recorded for Chione closed in Oct 2025. Shizune tracks 7 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co